- In January 2024, Merck KGaA entered into a five-year agreement with India's Heavy Water Board (HWB) to locally manufacture deuterated compounds. This collaboration aims to enhance the availability of stable isotope-labeled compounds in India, supporting the growing pharmaceutical and diagnostic sectors.
- In March 2024, Cambridge Isotope Laboratories (CIL) announced the relocation and expansion of its headquarters to Tewksbury, Massachusetts, . This move is designed to enhance the company's operational capabilities and support its growth in the stable isotope-labeled compounds market.
- In January 2022, Merck KGaA announced the expansion of its Stable Isotope Center of Excellence in Miamisburg, Ohio. The new infrastructure increases production capacity of GMP-grade urea-13C Active Pharmaceutical Ingredients, supporting the demand for stable isotope-labeled compounds in clinical diagnostics
- In September 2022, Cambridge Isotope Laboratories (CIL) announced a partnership with ISO topic Solutions to release stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts. These products are designed for use in mass spectrometry lipidomics research and development
- In May 2024, Shimadzu Corporation introduced a new line of stable isotope-labeled compounds designed for enhanced accuracy in mass spectrometry and pharmaceutical research. This launch strengthens Shimadzu’s position in Asia-Pacific, supporting growing demand for precise analytical tools in life sciences and clinical diagnostics.
